Form 4: Director Michael Perry Receives ARWR Stock Grant

Arrowhead Pharmaceuticals director Michael Perry was granted 7,819 shares of common stock as restricted stock units, vesting in one year.

Summary

• Michael S. Perry, a Director of Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 7,819 shares of common stock.
• These shares represent restricted stock units (RSUs) granted on December 16, 2025.
• The RSUs will vest in a single installment on the first anniversary of the grant date, subject to Mr. Perry's continued service to the Issuer on such date.
• Following this transaction, Mr. Perry beneficially owns 123,059 shares of Arrowhead Pharmaceuticals common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning management interests with shareholders, but does not contain significant news to dramatically shift sentiment.

Positives

• Director Michael Perry received a grant of 7,819 restricted stock units, aligning his interests with shareholders.
• The grant price of $0 indicates an equity incentive, a common practice for director compensation, fostering long-term commitment.

Risks

• The vesting of the 7,819 restricted stock units is contingent upon Michael Perry's continued service to Arrowhead Pharmaceuticals, Inc.

Future Outlook

The grant of restricted stock units indicates a long-term incentive for the director, aligning future performance with shareholder value and promoting continued service to the company.

Industry Context

Equity grants, particularly restricted stock units, are a standard component of director compensation packages in the biotechnology and pharmaceutical industries, aiming to retain talent and align interests with long-term company performance.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is a common practice across the pharmaceutical and biotech sectors, comparable to companies like Moderna (MRNA) or Pfizer (PFE) which also utilize equity-based incentives to align executive and director interests with shareholder value.
• The vesting schedule of one year is typical for such grants, providing a balance between immediate incentive and long-term commitment, similar to practices observed at companies such as Gilead Sciences (GILD) or Amgen (AMGN).

Corporate Governance

Stakeholder Impact

• Shareholders: Interests are further aligned with the director through equity ownership, potentially fostering long-term value creation.
• Employees: No direct impact mentioned.

Next Steps

• The 7,819 restricted stock units are expected to vest on December 16, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director, which is a standard compensation practice and aligns management interests with shareholders. It does not provide new information that would fundamentally alter the investment thesis for Arrowhead Pharmaceuticals, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Arrowhead Pharmaceuticals, ARWR, Michael Perry, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership